MedPath

Shared Decision for Drug Interactions in Oral Anticoagulation

Not Applicable
Recruiting
Conditions
Anticoagulants
Drug Interactions
Interventions
Other: Shared Decision Making Tool
Registration Number
NCT06401863
Lead Sponsor
University of Utah
Brief Summary

The purpose of this project is to implement and evaluate a shared-decision making (SDM) tool called DDInteract that was developed to support decision making for drug-drugs interactions while on oral anticoagulants. DDInteract will be implemented in clinics at the University of Utah, University of Colorado and University of Vanderbilt. DDInteract will be launched from within the electronic health record (EHR) retrieving patient-specific risk factors, will calculate the risk of harm, and will allow providers and patients to dynamically explore "what if" scenarios to optimize treatment and minimize risk. DDInteract will enable shared-decision making using individually-tailored information on the potential benefits and harms of drug interactions in anticoagulated patients.

Detailed Description

The purpose of this project are: 1) Examine contextual factors and define relevant implementation strategies to facilitate integration of DDInteract within 3 university-based healthcare systems; 2) Evaluate DDInteract in production/real-world situations to identify barriers and facilitators to adoption and use of DDInteract and to develop solutions to overcome those barriers; 3) Conduct a cluster randomized, multi-system trial to evaluate the effectiveness of DDInteract to mitigate exposure to drug interactions involving oral anticoagulants This project will implement a SDM tool designed to inform clinicians and patients about the risk of harm from drug interactions in patients receiving oral anticoagulants. An initial version of the DDInteract will be EHR-integrated and will be accessed directly in the EHR and auto-populate relevant patient-specific data including other medications that might interact with oral anticoagulants.

This study will use a multi-center randomized cluster design using clinics from the above-mentioned institutions. Each organization will implement DDInteract in their electronic health record system and the study will evaluate the degree to which the tool is utilized within each organization. The implementation period will last 18 months. This project is supported by a R18 award from Agency for Healthcare Research and Quality (AHRQ).

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
3691
Inclusion Criteria
  • Be at least 21 years of age or older
  • Receive more than one prescription of an oral anticoagulant (i.e. warfarin, apixaban, edoxaban, dabigatran, rivaroxaban)
Exclusion Criteria
  • Individuals not able to speak English or Spanish

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Exposure to DDInteract tool in anticoagulated patientsShared Decision Making ToolThis population will consist in outpatient clinics who treat oral anticoagulated patients where DDInteract has been implemented. This intervention is referred to as DDInteract tool exposure in anticoagulated patients. DDInteract may be accessed by clinicians to evaluate risk of harm from drug-drug interactions for patients on anticoagulants.
Primary Outcome Measures
NameTimeMethod
Differences of Differences in Estimated Risk of Gastrointestinal Bleeding by DDInteract algorithmThrough study completion, an average of 18 months for the implementation period and 12 months for the baseline period clinics

We will compare population Gastrointestinal Bleeding risk across the randomized clinics before and after implementation of DDInteract

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (3)

University of Colorado. School of Medicine

🇺🇸

Denver, Colorado, United States

Vanderbilt University

🇺🇸

Nashville, Tennessee, United States

University of Utah

🇺🇸

Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath